1. Scrip
  2. >>Focus On Asia
  3. >>Japan

Shionogi Moves To Build Pipeline Amid Progress Challenges

Obesity, Pain Assets Highlighted At R&D Day

 
• By Lisa Takagi

Shionogi unveiled its latest pipeline update, including a focus on long-standing key areas such as HIV and COVID-19 and a new obesity candidate, at its recent R&D Day, amid struggles to line up new products for launch over the next few years. The Japanese firm also seems set to seek further in-licencing collaborations.

Shionogi announced its R&D strategy while admitting struggle for new candidates
Shionogi updates R&D strategy while admitting struggle for new candidates • Source: Shutterstock

While preparing to submit the highly anticipated Phase III results for it oral COVID-19 antiviral Xocova (ensitrelvir; S-217622), Shionogi & Co. Ltd. is facing a struggle to line up other candidates for launch over the next few years.

At its recent R&D Day event, CEO Isao Teshirogi conceded the Japanese firm has been facing “a huge challenge” in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

Publisher’s Spotlight: Shortlist Unveiled For Citeline Japan Awards

 
• By Ian Haydock

Shortlists of potential winners in all categories of the Citeline Japan Awards 2025 have now been released. Join us at the event in Tokyo on October 21, it’s not too late to book your table!

Mitsubishi Tanabe Names New CEO In C-Suite Reshuffle

 
• By Lisa Takagi

Under new owner Bain Capital, the Japanese firm is aiming to regain its global presence, helped by new top executives formerly with Pfizer Japan and Takeda.

Nippon Kayaku Aims To Broaden Portfolio Via Singaporean JV

 
• By Lisa Takagi

Mid-sized, diversified Japanese group teams up with Singaporean wholesaler Formiica and Japanese trading/contract services firm CBC for Singapore JV focused on in-licensing in Asia/Oceania.

Japan Results Roundup: Reduced Forex Impact, Uncertain US Tariff Outlook

 
• By Lisa Takagi

Most major Japanese firms report generally positive fiscal first quarter results, led by mainstay growth and despite lower currency effects. But the future impact of any US pharma tariffs remains an overhang.

More from Focus On Asia

Biokin/BMS, Genfleet/Verastem’s Drug Candidates Impress At WCLC

 
• By Dexter Jie Yan

With data generated from China-only trials and consistency issues lingering, Chinese drug makers presented impressive results from early-stage studies of their assets at the World Conference on Lung Cancer annual conference.

The Rise In China Deals: How International Biopharma Is Turning To China For Innovation

 
• By Joseph Haas, Mary Jo Laffler, and Nancy Pham

The rapid growth of Chinese biopharmas has led to increased dealmaking with the US and Europe, but that could be stifled by a potential new Trump Administration policy.

Indigenization, AI Drive ICMR, Gennova, Zydus Vaccine Efforts In India

 
• By Vibha Ravi

Indian firms are upping indigenization, exploring AI application and expanding use of technology platforms like self-amplifying mRNA to develop vaccines against age-agnostic diseases like malaria, dengue, flu and Nipah encephalitis